In a pioneering effort to harness cutting-edge artificial intelligence (AI) technologies for clinical benefit, Sylvester researchers are co-leading the PRISM Trial—a $16 million multi-center study funded by the Patient-Centered Outcomes Research Institute (PCORI). This large-scale pragmatic randomized trial endeavors to assess whether AI can augment radiologists’ accuracy in interpreting mammograms. By evaluating hundreds of thousands of scans across diverse geographic settings, including California, Florida, Massachusetts, Washington, and Wisconsin, this research aims to redefine breast cancer screening protocols and reduce diagnostic errors. Such integration of AI holds promise not only for earlier detection but also for diminishing the burdens of false positives and negatives that compromise patient outcomes.

On the neurological oncology front, Sylvester’s investigations into glioblastoma—the most aggressive and lethal form of brain cancer—have yielded transformative insights into tumor cell behavior. Contrary to prior assumptions emphasizing isolated cellular aggression, this research uncovers that glioblastoma cells exhibit a spectrum of adhesive behaviors. Cells that remain “clustered” tend to be less malignant, whereas those that disengage from their neighboring cohorts demonstrate heightened invasiveness and lethality. Extending these observations to breast cancer tissues suggests a broader oncological paradigm wherein cellular cohesion influences metastatic potential. This discovery, published in the esteemed journal Cancer Cell, paves the way for novel therapeutic strategies that could target tumor cell adhesion mechanisms to retard cancer progression.

Meanwhile, the landscape of hematologic malignancies continuously evolves, underscored by Sylvester’s critical evaluation of AI tools such as ChatGPT in patient education and clinical decision support. Researchers critically appraised ChatGPT’s responses to pertinent blood cancer queries, revealing a dichotomy: while the AI excelled in addressing general oncology questions, it exhibited deficiencies when discussing cutting-edge therapies and nuanced treatment modalities. This underscores the imperative for patients and clinicians alike to approach AI-generated medical information with prudent skepticism. As advanced therapies rapidly emerge in hematology, expert oversight remains indispensable to ensure patient safety and optimal care.

In parallel endeavors, Sylvester scientists have meticulously charted the timeline of genomic insults culminating in multiple myeloma, the second most prevalent blood cancer. Leveraging sophisticated genome sequencing and molecular profiling techniques, this study delineates a chronology of DNA damage events that precede symptomatic disease. By unlocking the intricacies of these genetic trajectories, researchers aim to classify multiple myeloma into biologically and clinically relevant subtypes. Such refined stratification holds profound implications for the advancement of precision oncology, enabling tailored treatment regimens that optimize efficacy and minimize toxicity.

Expanding the molecular understanding of lymphoma, a Sylvester-led team secured a substantial $2.4 million grant from the National Cancer Institute to explore the role of the cyclin G-associated kinase (GAK) protein in diffuse large B-cell lymphoma (DLBCL). This investigation probes uncharted facets of lymphoma biology, particularly how GAK modulates cellular processes driving oncogenesis. Unveiling these mechanisms may herald new drug targets, offering therapeutic avenues beyond conventional chemotherapeutic strategies. This initiative exemplifies the relentless pursuit of innovation in combating hematologic cancers.

Complementing these advances in cancer biology and therapeutics, Sylvester Cancer Center’s clinical research affirms the transformative potential of remote perioperative monitoring (RPM) in enhancing postoperative outcomes for cancer patients. In a controlled trial involving approximately 300 surgery recipients, RPM facilitated real-time patient assessment during the critical two-week post-surgical window, significantly reducing complications and accelerating recovery. By integrating wearable sensors and telehealth platforms, RPM empowers clinicians to swiftly identify and address adverse events, thereby elevating standards of care and patient satisfaction.

Leadership at Sylvester continues to influence the broader oncology community, exemplified by Dr. Mikkael Sekeres’s election to the executive committee of the American Society of Hematology (ASH). This appointment reflects Sylvester’s commitment to shaping hematology research and clinical practice at national and international levels, further cementing the center’s role as a vanguard institution in blood cancer management.

These collective efforts underscore a multidisciplinary approach that synergizes environmental health, artificial intelligence, molecular biology, and patient-centered care. As cancer remains a formidable global health challenge, innovations emanating from Sylvester Comprehensive Cancer Center invigorate hope for more effective interventions and improved survival rates across diverse malignancies.

The integration of environmental data with oncological outcomes exemplifies the expanding paradigm of cancer research—recognizing that genetics alone cannot account for disparities in cancer aggressiveness. Likewise, the incorporation of AI into diagnostic workflows anticipates a future where augmented intelligence bolsters human expertise rather than supplants it. Novel findings regarding tumor cell adhesion dynamics invite a reevaluation of metastasis models, suggesting therapeutic targeting of physical cell-cell interactions.

Moreover, scrutinizing AI’s performance in conveying complex medical information serves as a cautionary tale, emphasizing that technology is a complement, not a replacement, for professional medical judgment. Genetic mapping of disease progression in multiple myeloma and molecular characterization of lymphoma biology both herald precision medicine’s promise, fostering treatments attuned to individual patient profiles.

Finally, the successful implementation of remote-monitoring technologies during vulnerable recovery periods offers a template for leveraging digital health to enhance surgical outcomes and patient quality of life. These advancements collectively chart an optimistic trajectory for the future of oncology research and care, grounded in rigorous science and multidisciplinary collaboration.

Subject of Research: Cancer biology, environmental health impacts, AI in diagnostic imaging, hematologic malignancies, surgical recovery monitoring
Article Title: October 2025 Cancer Research Highlights from Sylvester Comprehensive Cancer Center: From Toxic Sites to AI and Beyond
News Publication Date: October 2025
Web References:
– Sylvester Comprehensive Cancer Center: https://umiamihealth.org/en/sylvester-comprehensive-cancer-center
– PRISM Trial on AI in Mammography: https://news.med.miami.edu/studying-artificial-intelligence-in-breast-cancer-screening/
– Glioblastoma Cell Adhesion Study in Cancer Cell: https://www.cell.com/cancer-cell/fulltext/S1535-6108(25)00366-6
– ChatGPT Blood Cancer Accuracy Study: https://www.tandfonline.com/doi/full/10.1080/20565623.2025.2546259
– Multiple Myeloma DNA Damage Timeline in Nature Genetics: https://www.nature.com/articles/s41588-025-02292-1
– Remote Perioperative Monitoring Study in npj Digital Medicine: https://www.nature.com/articles/s41746-025-01961-z
– American Society of Hematology: https://www.hematology.org/
References: Links as indicated above
Image Credits: Photo by Sylvester Comprehensive Cancer Center
Keywords: Cancer research, Translational research, Blood cancer, Brain cancer, Breast cancer, Leukemia, Lymphoma, Multiple myeloma

Conventional medical diagnostics often involve sending blood or tissue samples to centralized clinical laboratories, where specialized personnel perform intricate testing and data interpretation. This process can be time-consuming and costly, creating barriers for many patients, especially those who face logistical, financial, or geographical limitations in accessing healthcare facilities. Recognizing these challenges, the research team, led by graduate student Han Lee and Professor Brian Cunningham at the University of Illinois at Urbana-Champaign, set out to develop a solution that brings diagnostic power directly to the patient’s side.

Point-of-care testing refers to medical testing performed at or near the site of patient care, ranging from home settings to clinics or specialist appointments. By providing rapid, easy-to-use, and cost-effective diagnostic tools, these technologies enable clinicians and patients to make timely decisions that can dramatically improve health outcomes. Examples such as home pregnancy kits, at-home COVID-19 antigen tests, and blood glucose meters for diabetes management have already demonstrated how point-of-care devices can revolutionize healthcare delivery and patient autonomy.

The team’s breakthrough stems from advancing a cutting-edge biosensing technique originally reported in prior studies, called Photonic Resonator Absorption Microscopy—or PRAM. PRAM offers an unprecedented ability to detect individual biomarker molecules such as nucleic acids, antigens, and antibodies, which act as critical indicators of physiological or pathological states. Unlike many biosensors that measure the collective signal generated by thousands of molecules, PRAM achieves digital resolution by identifying single molecules, significantly enhancing detection sensitivity and diagnostic precision.

At its core, PRAM operates by shining red LED light onto a sophisticated photonic sensor where target molecules tagged with gold nanoparticles (AuNPs) bind to the surface. These AuNPs, minuscule particles approximately 1,000 times smaller than human hair, create detectable contrast spots against a red background when imaged. However, the raw images generated can be difficult to interpret because of the presence of artifacts such as dust, nanoparticle aggregates, or noise. Traditionally, accurately counting the true biomarker-related signals demands extensive expertise and manual adjustment of thresholding parameters, limiting the scalability and applicability of PRAM in everyday clinical use.

To overcome these challenges, Han Lee developed a novel integration of advanced machine learning algorithms with PRAM, pioneering a method termed Localization with Context Awareness (LOCA). This approach leverages deep learning techniques to automatically analyze PRAM images, accurately distinguishing genuine biomarker signals from artifacts, and enabling real-time, high-precision molecular detection. The incorporation of artificial intelligence dramatically reduces dependence on human expertise, facilitating point-of-care deployment by non-specialists and patients themselves.

Because machine learning models rely heavily on the quality of their training data, the researchers adopted an innovative validation strategy. Lee painstakingly imaged identical biomarker samples using both PRAM and scanning electron microscopy (SEM). SEM provides ultra-high-resolution images where individual AuNPs are clearly distinguishable, serving as a ground truth reference to annotate spots in the PRAM images precisely. This labor-intensive cross-validation process was akin to finding a needle in a haystack, requiring the creation of reference landmarks to reliably match image areas across the two different microscopy platforms.

The resulting dataset empowered the training of a physically grounded deep learning model capable of interpreting complex microscopic image features in PRAM while factoring in physical realities of nanoparticle behavior and sensor optics. When tested, LOCA-PRAM demonstrated remarkable improvements over conventional image analysis algorithms, exhibiting enhanced sensitivity in detecting lower biomarker concentrations and substantially reducing false-positive and false-negative rates. This leap in analytical performance opens the door to reliable and widespread clinical application of PRAM technology.

Professor Brian Cunningham emphasizes the clinical potential of rapid, point-of-care diagnostics powered by this technology. Physicians often encounter bacterial infections treated empirically with broad-spectrum antibiotics due to lack of rapid identification of the causative agent. LOCA-PRAM’s capability suggests a future where cancer patients could receive tailored therapeutic guidance during routine appointments, quickly determining the most effective anti-cancer drugs or monitoring treatment efficacy shortly after initiation. Such timely interventions could dramatically improve patient outcomes and reduce unnecessary side effects.

This project exemplifies how interdisciplinary collaboration—combining electrical and computer engineering, materials science, and biomedical research—can yield technologies that bridge fundamental science and clinical practice. The implementation of machine learning in biosensing not only exemplifies technical ingenuity but also reflects a commitment to addressing real-world healthcare disparities by enhancing diagnostic accessibility.

Han Lee’s journey highlights the transformative power of curiosity and cross-field learning. Inspired by a university course in machine learning, Lee independently explored how artificial intelligence could solve persistent image interpretation problems in biosensing. The result is not merely an academic advance but a potentially life-saving technology that contributes meaningfully to the evolution of personalized medicine and global health.

Published in the journal Biosensors and Bioelectronics, the study titled “Physically grounded deep learning-enabled gold nanoparticle localization and quantification in photonic resonator absorption microscopy for digital resolution molecular diagnostics” represents a significant milestone in biosensor development. Supported by prominent funding agencies including the National Institutes of Health, the USDA AFRI Nanotechnology grant, and the National Science Foundation, this research lays foundational work for next-generation diagnostic devices.

As the medical field moves towards more decentralized, patient-centered care, technologies like LOCA-PRAM could redefine how we detect, monitor, and manage diseases in real-time. This innovative blend of nanotechnology, photonics, and artificial intelligence heralds a new era of precision diagnostics—one where critical health information can be accessed rapidly and affordably, empowering both patients and practitioners alike. The implications for public health, especially in underserved communities, are profound and far-reaching.

Subject of Research: Biosensing technology, machine learning integration, and point-of-care molecular diagnostics

Article Title: Physically grounded deep learning-enabled gold nanoparticle localization and quantification in photonic resonator absorption microscopy for digital resolution molecular diagnostics

Web References: https://doi.org/10.1016/j.bios.2025.117455

References: Supported by National Institutes of Health, USDA AFRI Nanotechnology grant, and National Science Foundation

Image Credits: Julia Pollack

Keywords: Machine learning, Photonic crystals, Gold nanoparticles, Biomarkers, Medical diagnosis